anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an organic-inorganic double-shell microcapsule for temperature-controlled release of hydrophobic micromolecules and a preparation method thereof. At present, researches on preparation of microcapsules from chitosan and silicon dioxide used as double-wall materials are rarely reported in public. The preparation method comprises the following steps: simultaneously adding an amphiphilic triblock copolymer, a silicon dioxide precursor, a silane coupling agent and a hydrophobic micromolecule substance into an organic solvent, and dissolving by stirring at room temperature so as to obtain a mixed liquor; adding 90-150 mg of chitosan powder into a weak acidic solution to obtain a chitosan dissolved solution; gradually dropwise adding the mixed liquor into the chitosan dissolved solution at room temperature and carrying out ultrasonic treatment so as to obtain the organic-inorganic double-shell microcapsule for temperature-controlled release of hydrophobic micromolecules. By an interfacial polymerization method, the double-wall microcapsule with chitosan used as an outer shell and silicon dioxide used as an inner shell is obtained. Release rate of a core material is gradually reducing with the rising of temperature. The microcapsule has an obvious temperature-controlled release effect on hydrophobic micromolecules, and release efficiency is high.
Three study drugs will be used in this study: Testim (testosterone gel), Human Chorionic Gonadotropin (hCG) and acyline. Testosterone is a naturally occurring hormone in men. When given to normal men, testosterone gel will temporarily lower the amount of testosterone in the testes and lower sperm counts. hCG is a female hormone produced during pregnancy that is similar to and has the same actions as a male hormone, luteinizing hormone (LH). Like LH, hCG stimulates the testis to produce testosterone and sperm, and is used in the treatment of men who are deficient in LH. When hCG is given together with testosterone to normal men, the amount of testosterone in the testes will change, dependent on the amount of hCG received. Some participants will receive placebo hCG injections (no active medication).

Acyline suppresses LH (luteinizing hormone) and FSH (follicle stimulating hormone), which are hormones made by the pituitary gland in the brain, thus blocking the signal from the brain that causes the testes to make testosterone. Therefore, acyline blocks testosterone production. Men may experience some side effects from the low levels of testosterone caused by acyline.

Acyline is an experimental drug. Testosterone gel and hCG are approved for use in men with low testosterone levels. The U.S. Food and Drug Administration (FDA) allows testosterone gel, hCG and acyline to be given in combination for research to a small number of volunteers. Over 125 men have received acyline. Both Acyline and hCG will be given by injection. Acyline injections are formulated by subjects weight and may be given in multiple injections.

Participation will last approximately 2 months. The study involves a minimum of 9 visits in Seattle, WA. Clinic visits at Screening, Day 1 and Day 10 will take about 1-1.5 hours each. On Day 1 \& 10 a fine needle aspiration of one testis will be performed. The Day 7, Day 17, and Day 40 visits will take approximately 30 minutes. The other visits will take about 15 minutes each time. Over the course of the study, which includes 5 separate blood draws, approximately 12 ounces (one and a half cups) of blood will be drawn. Some of the study drugs will be given by injection. One drug is a topical gel.

This is NOT a trial of a male contraceptive, and the study medications will not prevent pregnancy. Subjects must use an acceptable form of birth control.
An apparatus and a method for dispersing particulate materials prone to agglomeration, in a liquid. Particulate materials are exposed to a liquid and put into that liquid to form a suspension or a dispersion in a controlled method thereby minimizing agglomerates. The method uses mechanical/hydro mixing that prevents the physical deterioration of the particulate material and inhibits agglomeration of the particles. In many cases, these materials may be nanomaterials. Almost all particulate materials can be handled in this manner. This method has been found to be especially useful for preparing solutions of exfoliated graphene and certain drugs.
Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain \<35 ng/ml, subjects will receive additional doses of narrow band UVB.
A vaporizable decongestant is supported and stabilized on a flexible foraminous carrier composed typically of open-cell plastic foam, cloth or other fibrous material such as nonwoven fabric. The term "foraminous" herein is intended to refer to a substance or medium containing minute openings or perforated by many minute apertures. The decongestant is placed on the surfaces within the interstices and minute apertures or on fibers from which the foraminous carrier is formed. Vaporization of the inhalable decongestant is facilitated by providing the potential for greatly increasing its exposed surface area. Distributing the decongestant composition over the large, expanded surface within the foraminous carrier is beneficial in enhancing both the volatilization and evaporation of the decongestant agent. It also prolongs the useful life of the product. Once vaporized, the aromatic decongestant is available for natural inhalation through the nose or mouth to help relieve one or more of the symptoms of cough, colds, nasal or chest congestion and related symptoms. The foraminous carrier is preferably provided in the form of a patch or sheet that is bonded to the skin to serve as a supporting base for the active decongestant agent. The patch defining the carrier is typically adhesively bonded to the upper part of the body, e.g. on the face, neck or chest, in a location where the decongestant is liberated into the air and can be inhaled through the mouth or nose.
Levopront® (levodropropizine) syrup 30 mg/5 ml 10 ml (60 mg) t.i.d. for 7 days. The study drugs was taken 3 times a day, at intervals of at least 6 hours, between meals for 7 days.
FIELD: medicine, virology. SUBSTANCE: vaccination against viral hepatitis B is carried out for two stages with vaccine containing hepatitis B virus antigen obtained by culturing the transformed cells of the strain S. cerevisiae VKPM-Y-2203. The second administration of vaccine is carried out mainly in 4-5 months after the first one. By emergency indications the second administration is carried out in 2-3 months after the first one. Invention can be used in medicine for prophylaxis and propagation of viral hepatitis B. EFFECT: high frequency of seroconversions, significant level of immunity. 3 cl, 1 tbl
Alcohol use disorder stands as a prevalent global issue, contributing to 140,000 annual deaths in the United States and causing numerous adverse health and socioeconomic outcomes. Despite being a natural physiological process, menopause often leads to troublesome symptoms that affect women's quality of life and exposes them to increased health risks. Our review delves into the intricate relationship between alcohol use disorder and the menopausal experience. We examine the impact of heightened alcohol consumption on the onset, severity, and burden of menopausal symptoms, particularly vasomotor symptoms. Additionally, we explore its effects on commonly experienced menopausal symptoms such as mood disturbances, sleep problems, and sexual dysfunction. Considering the chronic health conditions associated with both menopause and alcohol use disorder, our study also investigates the influence of alcohol use disorder on bone density. This is especially important due to the elevated risks and mortality linked to bone mineral density loss in menopausal women.
The control group will receive the physical function survey at weeks 0, 8, 16, and 24; the physical activity survey at weeks 0, 12, and 24; the events survey at weeks 0, 4, 8, 12, 16, 20, and 24. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
Myocarditis is characterized by an influx of inflammatory cells, predominantly of myeloid lineage. The progression of myocarditis to a dilated cardiomyopathy is markedly influenced by TGF-β signalling. Here, we investigate the role of TGF-β signalling in inflammatory cardiac macrophages in the development of myocarditis and post-inflammatory fibrosis. Experimental autoimmune myocarditis (EAM) was induced in the LysM-Cre × R26-stop-EYFP × Tgfbr2-fl/fl transgenic mice showing impaired TGF-β signalling in the myeloid lineage and the LysM-Cre × R26-stop-EYFP control mice. In EAM, immunization led to acute myocarditis on day 21, followed by cardiac fibrosis on day 40. Both strains showed a similar severity of myocarditis and the extent of cardiac fibrosis. On day 21 of EAM, an increase in cardiac inflammatory macrophages was observed in both strains. These cells were sorted and analysed for differential gene expression using whole-genome transcriptomics. The analysis revealed activation and regulation of the inflammatory response, particularly the production of both pro-inflammatory and anti-inflammatory cytokines and cytokine receptors as TGF-β-dependent processes. The analysis of selected cytokines produced by bone marrow-derived macrophages confirmed their suppressed secretion. In conclusion, our findings highlight the regulatory role of TGF-β signalling in cytokine production within inflammatory cardiac macrophages during myocarditis.
1,139,993. Acrylic acid derivatives. GEBRUDER GIULINI G.m.b.H. 7 March, 1967 [8 March, 1966 (2)], No. 10755/67. Heading C2C. Novel acrylic acid derivatives having the general formula R 1 R 2 C =CR 3 -COOH wherein R 1  is a phenyl group which may optionally be substituted by an alkyl or alkoxy group; or an alkyl group containing at least two carbon atoms or, when R 2  is an aralkyl or thienyl group, a methyl group; R 2  is a phenyl group substituted by an alkyl or alkoxy group, an alkyl group; an aralkyl or thienyl group; or, when R 1  is a phenyl group, a phenyl group; R 3  is an alkyl group containing at least 3 carbon atoms or, when R 2  is a substituted phenyl group or an alkyl group, an ethyl group; and also novel acrylic acid derivatives of the said general formula wherein R 1  is as defined above, R 2  is a phenyl group which is substituted by an alkyl or alkoxy group, an alkyl group; or a benzyl or thienyl group; and R 3  is an alkyl group containing at least two carbon atoms; and non-toxic salts thereof are prepared by saponification of an ester of the acrylic acid derivative with an alkali, followed by optional salt formation. Pharmaceutical compositions having choleretic activity comprise at least one acrylic acid derivative of the above general formula or a non-toxic salt thereof together with a pharmaceutical carrier or excipient.
ETHNOPHARMACOLOGICAL RELEVANCE: The Niaodukang mixture (NDK) is a preparation known for its ability to lower serum creatine levels in individuals with chronic kidney disease (CKD) and is commonly administered at medical facilities like the Zhongshan Hospital of Traditional Chinese Medicine. The initial use of NDK was mainly to treat CKD. Our hospital frequently utilizes NDK, which consists of Rheum officinaleBaill., Salvia miltiorrhiza Bunge., Astragalus aaronii (Eig) Zohary., Carthamus tinctorius L., and Sanguisorba officinalis L., for treating patients with CKD-MBD. It has the effects of eliminating dampness and turbidity and dredging kidney collaterals. However, The impact and process of NDK in chronic kidney disease remain unknown.
AIM OF THE STUDY: To determine whether microRNA-146a (miR-146a) is associated with CKD micro-inflammationand whether NDK protects against CKD micro-inflammation by modulating the miR-146a/nuclear factor kappa-B (NF-κB) signaling pathway.
MATERIALS AND METHODS: (1) An adenine-induced rat model of chronic kidney disease was created through the use of materials and methods. The levels of miR-146a in exosomes from plasma and ileum were determined by RT-PCR. (2) Human cloned colon adenocarcinoma (Caco-2)cellswere stimulated with lipopolysaccharide (LPS)and transfected with miR-146a mimic and inhibitor. Following that, the Western blot and RT-PCR techniques were used to measure the protein and mRNA quantities of Toll-like receptor 4 (TLR4), NF-κB, and TNF receptor-associated factor 6 (TRAF6). (3) Enzyme-linked immunosorbent assay (ELISA) was used to identify serum levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α). (4) Plasma exosomes were extracted, and the exosomes in intestinal tissues were extracted via ultrahigh-speed centrifugation.Negative staining electron microscopy was used to analyze the morphology of exosomes and the ultrastructure of intestinal tissue and exosomes. The particle size of the exosomes was measured using nanoparticle tracking analysis.
RESULTS: The pathological characteristics of CKD rats included those associated with systemic micro-inflammation, which may be associated with the release of exosomes in intestinal tissue. NDK suppressed the inflammatory response in Caco-2 cells and decreased the levels of IL-1β, IL-6, and TNF-α in rats with CKD. The expression of miR-146a, which regulates inflammation, differed between plasma-derived and enterogenous exosomes in CKD rats, which may be due to stimulation of ileal exosome release into the blood. NDK effectively reduced the levels of TRAF6, NF-κB, and TLR4 in the ileum tissue of CKD rats.
CONCLUSION: NDK can effectively improve micro-inflammation in CKD ratsby enhancing the release of enterogenous exosomes, thereby enhancing the release of exosome-associated miR-146a and inhibiting micro-inflammation.
Many of the tasks performed regularly by physiotherapists during any given rehabilitation session are repetitive and do not rely on the physiotherapist's expertise, and could be performed and observed by automated means. The developed system will detect patient body postures and movements with data collected through sensors such as accelerometers. This data will be pattern matched to a predetermined movement pattern and feedback will be provided for patients regarding accuracy of their exercises. This data can be logged for the physiotherapist to examine at a later time. By automating this component of a rehabilitation session, the system will allow the physiotherapist to focus diagnosis and other tasks that will better utilize their training. The specific application for this prototype will be post-operative knee/hip replacement patients, so all devices must be non-invasive and must not interfere with normal recovery processes.

A previous version of this experiment on healthy participants has been successfully performed. This study would like to examine the feasibility of this system on rehabilitation subjects, as the movement patterns of a subject in physical rehabilitation may be dramatically different then a healthy subject. No intervention is suggested by the system, as this study is observational.
Nearly 1 in 60 adolescent athletes will suffer ACL injuries. Approximately 90% of these injured athletes will undergo an ACL reconstruction at an estimated annual cost of $3 billion. While reconstruction and subsequent rehabilitation allow these athletes to return to sports, they have a 15 fold increased risk of secondary ACL injuries, a tear of the ACL graft or the contralateral ACL. As a result, development of an intervention to reduce the incidence of secondary ACL tears would meet a critical need. One area in which existing interventions might be improved is through an increased emphasis on correcting asymmetric movement patterns-a known risk factor for secondary injury. Thus, our long-term objective is to decrease the number of secondary ACL tears by decreasing side-to-side movement and loading asymmetry. The modification of post-operative rehabilitation to focus on movement and loading symmetry with shift the rehabilitation paradigm. Specifically, we propose to evaluate a novel biofeedback training program that focuses on altering loading and movement patterns to improve symmetry and overall lower extremity mechanics in a group of 40 (20 control, 20 intervention) adolescent ACL reconstructed patients. There are two core hypotheses of this study: 1) biofeedback training will decrease known risk factors for secondary ACL injuries immediately following the biofeedback program and these changes will be retained 6 week after the completion of the biofeedback program; and 2) we will be able to recruit and enroll 40 patients and retain 80% of the patients through the end of the follow-up assessment demonstrating the feasibility of the biofeedback intervention. Implementation of a biofeedback program prior to returning to dynamic athletic activities could improve physical performance outcomes, decrease secondary injury risk factors and ultimately decrease the long-term joint degeneration and development of osteoarthritis that has been associated with ACL reconstruction. Ultimately this work will lead to additional investigations to definitively determine the impact of this novel biofeedback program, which could shift the post-operative rehabilitation paradigm following ACL reconstruction to improve long-term joint health in these adolescent patients.
Participants with HER2 proto-oncogene positive breast cancer were treated with doxorubicin 60 mg/m\^2, IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
The invention relates to a preparation method of lactation promoting powder. According to the invention, dry sponge gourd is chopped; black sesame, Mongolian milkvetch root, radix angelicae sinensis, pilose asiabell root and the like are dried; the materials are mixed and grinded into coarse powder; the powder is doped with wheat bran; the mixture is decocted with water, and an obtained decoction is orally taken. With the lactation promoting powder, breast milk shortage caused by qi and blood deficiencies can be solved. Blood is nourished, and the breast milk is promoted. The lactation promoting powder provides functions of both qi tonifying and blood nourishing. The preparation is simple, feasible, and has a good effect. The preparation is a good prescription for parturient in promoting lactation.
PURPOSE: This study was performed with the purpose of analysing the relationship between epileptological and surgical variables and post-operative memory performance, following surgery for refractory mesial temporal lobe epilepsy (MTLE) due to hippocampal sclerosis (HS).
METHODS: Logical memory (LM) and visual memory (VM) scores for immediate and late follow-up of 201 patients operated for MTLE/HS were reviewed. Scores were standardized with a control group of 54 healthy individuals matched for age and education. The Reliable Change Index (RCI) was calculated to verify individual memory changes for late LM and VM scores. A multiple linear regression analysis was carried out with the RCI, using LM and VM scores as well as the clinical variables.
RESULTS: A total of 112 (56%) patients had right HS. The RCI of the right HS group demonstrated that 6 (7%) patients showed improvement while 5 (6%) patients showed decreased scores in late LM; for late VM, 7 (8%) patients presented improvement, and 2 (3%) patients showed poorer scores. RCI of the left HS group showed that 3 (3%) individuals showed improved scores, while scores of 5 (4%) patients worsened for late LM; for late VM, 3 (3%) patients presented higher scores and 6 (5%) showed lower scores. Left HS and advanced age at onset of the first epileptic seizure were predictors of late LM loss (p<.05).
CONCLUSION: Left MTLE/HS and seizure onset at advanced ages were predictive factors for the worsening of late LM. We observed poorer baseline LM function in the left HS group and improvement of LM in some patients who had resection of the right MTL. Patients in the right HS group showed a higher percentage of reliable post-operative improvement for both VM and LM scores.
PURPOSE:To obtain a carcinogenesis preventing agent for inhibiting occurrence of cancer, containing the Chinese medicine KOSAIKOTO (blend of Bupleuri Radix with other ingredient) and having extremely low toxicity and high safeness. CONSTITUTION:A diluting agent, auxiliary agent, etc., used in a conventional formulation is added to a dried extract powder of KOSAIKOTO (a Chinese medicine) produced according to the blend ratio as described in old books such as SHOKANRON and KINKIYORYAKU, and formulated according to a conventional method to provide the aimed agent. The agent is orally administered in an amount of 1-10g / day / three time normally based on amount of adult as an amount of dried extract powder. A blend ratio of each crude medicine of KOSAIKOTO is illustrated by 4-7pts.wt. Bupleuri Radix, 3pts.wt. Scutellariae Radix, 2pts.wt. Glycyrrhizac Radix, 2-3pts.wt. Ginseng Radix, 1pt.wt. Zingiberis, 2-3pts.wt. Zizyphi Fructus and 4-5pts.wt. Pinelliae Tuber.
The safety and efficacy of sevelamer carbonate in lowering serum phosphorus levels was studied in patients 6 years of age and older with CKD. In this study, sevelamer carbonate was apparently less effective in children with a low baseline serum phosphorus, which described children <13 years of age and children not on dialysis. Given its mechanism of action, sevelamer carbonate is expected to be effective in lowering serum phosphorus levels in pediatric patients with CKD. Most adverse events that were reported as related, or possibly related, to sevelamer carbonate were gastrointestinal in nature. No new risks or safety signals were identified with the use of sevelamer carbonate in the trial.

Sevelamer carbonate tablets has not been studied in pediatric patients below 6 years of age.